Business · 27/02/2002Updated: 10/17/2026 · 1 min read
FDA Determines Regulatory Review Period for RELENZA Patent Extension
Summary
The US Food and Drug Administration (FDA) has officially confirmed the regulatory review period for the patent extension of RELENZA, a human drug product, following a submission to the Commissioner of Patents and Trademarks, Department of Commerce.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →